Medline ® Abstract for Reference 80
of 'Enterotoxicity of chemotherapeutic agents'
A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele.
Gusella M, Bolzonella C, Crepaldi G, Ferrazzi E, Padrini R
Pharmacogenomics J. 2006 Nov-Dec;6(6):421-4. Epub 2006 Jul 25.
Thymidylate synthase (TYMS) is the main molecular target for fluoropyrimidine anticancer drugs, and its expression has been correlated with the number of repeats of a 28-bp sequence in the 5'-untranslated region of the TYMS gene and with the presence of a G -->C single-nucleotide polymorphism in the second repeat of 3R alleles. Based on this double polymorphism, three main TYMS alleles have so far been identified: TYMS 2R, TYMS 3RC and TYMS 3RG. During genetic analysis of TYMS polymorphisms in 100 colorectal cancer patients, three patients revealed an unexpected 113-bp band after electrophoresis of the restriction fragment length polymorphism analysis. Subsequent sequencing revealed two 28-bp repeats in the 5'-untranslated region and the presence in both repeats of cytosine instead of guanine at the 12th nucleotide. This allele variant (TYMS 2RC) has not been previously described in man. All three patients were heterozygotes for TYMS 2RC and experienced grade 2-3 chemotherapy-related toxicity.
Oncology Unit, Rovigo Hospital, Rovigo, Italy. firstname.lastname@example.org